Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per year (NASDAQ:IMCR)
· seekingalpha.com
Immunocore (IMCR) Q2 2026 earnings call recap: KIMMTRAK sales, 5-year survival data, TEBE-AM timeline, cash/rebates & pipeline updates—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...